Teva Pharmaceutical Industries (TEVA) Non Operating Income (2017 - 2026)
Teva Pharmaceutical Industries (TEVA) recorded quarterly Non Operating Income of -$216.0 million in Q1 2026, up 1.82% on a QoQ basis from -$220.0 million in Q4 2025, and up 4.0% year-over-year from -$207.7 million in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Non Operating Income (2017 - 2026) Analysis & Trends
Teva Pharmaceutical Industries has disclosed Non Operating Income across 10 years of filings, most recently posting -$216.0 million for Q1 2026.
- Quarterly Non Operating Income rose 4.0% year-over-year to -$216.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$925.0 million (up 3.24% YoY) and the FY2025 annual result came in at -$934.0 million, up 4.79% from the prior year.
- Non Operating Income advanced to -$216.0 million in Q1 2026, from -$220.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at -$211.0 million in Q2 2022 and troughed at -$280.0 million in Q3 2023.
- A 5-year average of -$244.4 million and a median of -$249.0 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income rose 22.99% — and 2023, when it slipped 27.01%.
- Tracing TEVA's Non Operating Income over 5 years: stood at -$245.0 million in 2022, then decreased by 1.63% to -$249.0 million in 2023, then gained by 12.45% to -$218.0 million in 2024, then decreased by 0.92% to -$220.0 million in 2025, then gained by 1.82% to -$216.0 million in 2026.
- Business Quant data shows TEVA's Non Operating Income at -$216.0 million in Q1 2026, -$220.0 million in Q4 2025, and -$237.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -216.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 20.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -7.50 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -504,111.66 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 53.40 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -13.65 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 5.71 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -23.23 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | -4.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.00 Mn |
| Dec 31, 2025 | -220.00 Mn |
| Sep 30, 2025 | -237.00 Mn |
| Jun 30, 2025 | -252.00 Mn |
| Mar 31, 2025 | -225.00 Mn |
| Dec 31, 2024 | -218.00 Mn |
| Sep 30, 2024 | -272.00 Mn |
| Jun 30, 2024 | -241.00 Mn |
| Mar 31, 2024 | -250.00 Mn |
| Dec 31, 2023 | -249.00 Mn |
| Sep 30, 2023 | -280.00 Mn |
| Jun 30, 2023 | -268.00 Mn |
| Mar 31, 2023 | -260.00 Mn |
| Dec 31, 2022 | -245.00 Mn |
| Sep 30, 2022 | -252.00 Mn |
| Jun 30, 2022 | -211.00 Mn |
| Mar 31, 2022 | -258.00 Mn |
| Dec 31, 2021 | -253.00 Mn |
| Sep 30, 2021 | -241.00 Mn |
| Jun 30, 2021 | -274.00 Mn |